Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma

NCT00412997 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00412997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00412997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2006
Completion date
Not reported
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma, tumors